Nicholas Chew

Dr. Nicholas Chew is a distinguished Interventional Cardiologist and Clinician-Scientist based in Singapore. He serves as an Associate Consultant at the National University Heart Centre, Singapore (NUHCS) and holds academic appointments as an Adjunct Assistant Professor and Academic Fellow at the National University of Singapore (NUS). Dr. Chew’s educational background is extensive, including an MBChB from the University of Auckland, a Master of Medicine from NUS, and a Masters of Clinical Investigation. He is also a Member of the Royal Colleges of Physicians of the United Kingdom (MRCP UK).

Dr. Chew is recognized globally for his pioneering research in the cardiovascular-liver-kidney-metabolic health spectrum. With an impressive H-index of 44, he has led high-impact studies published in top-tier journals such as Nature Reviews Cardiology, Circulation, and The Lancet. His work focuses on the "global syndemic" of metabolic diseases and the management of metabolic dysfunction-associated steatotic liver disease (MASLD) within cardiovascular practice. Notably, he has been consistently named in Stanford University’s World’s Top 2% Scientists List from 2023 to 2025.

Beyond his research, Dr. Chew is a leader in clinical trial coordination and medical education. He serves as the National Principal Investigator for major Phase 3 international trials, including studies on novel oral Factor XIa inhibitors after acute coronary syndrome. His commitment to mentorship was recognized with the Outstanding Mentor Award from the Singapore Medical Association Charity Fund in 2023. He also holds key editorial roles, serving as an Associate Editor for Metabologia.